ICAAC 2015: Data Help Theravance's Ongoing Vibativ Relaunch

Theravance BioPharma senior vice president of development and operations Frank Pasqualone says the Vibativ (telavancin) relaunch "has gone just about as well as expected" and it has been helped by the company's growing collection of data for the intravenous antibiotic.

Theravance BioPharma senior vice president of development and operations Frank Pasqualone says the Vibativ (telavancin) relaunch "has gone just about as well as expected" and it has been helped by the company's growing collection of data for the intravenous antibiotic.

South San Francisco-based Theravance Biopharma presented data from multiple in vitro studies that showed Vibativ was superior to competing drugs...